Show simple item record

dc.contributor.authorKlimek, L; Jutel, M; Akdis, C; Bousquet, J; Akdis, M; Bachert, C; Agache, I; Ansotegui, I; Bedbrook, A; Bosnic-Anticevich, S; Canonica, GW; Chivato, T; Cruz, AA; Czarlewski, W; Del Giacco, S; Du, H; Fonseca, JA; Gao, YD; Haahtela, T; Hoffmann-Sommergruber, K; Ivancevich, JC; Khaltaev, N; Knol, EF; Kuna, P; Larenas-Linnemann, D; Melen, E; Mullol, J; Naclerio, R; Ohta, K; Okamoto, Y; O'Mahony, L; Onorato, GL; Papadopoulos, NG; Pawankar, R; Pfaar, O; Samolinski, B; Schwarze, J; Toppila-Salmi, S; Shamji, MH; Ventura, MT; Valiulis, A; Yorgancioglu, A; Matricardi, P; Zuberbier, T
dc.date.accessioned2023-03-02T06:40:04Z
dc.date.available2023-03-02T06:40:04Z
dc.date.issuedJUL
dc.date.issued2020
dc.identifier.urihttp://hdl.handle.net/20.500.12481/14437
dc.description.abstractThe current COVID-19 pandemic influences many aspects of personal and social interaction, including patient contacts with health care providers and the manner in which allergy care is provided and maintained. Allergen-specific immunotherapy (AIT) is one of the most important treatment options for IgE-mediated allergies and is based on inducing an appropriate immune response in the allergic patient. This manuscript outlines the EAACI recommendations regarding AIT during the COVID-19 pandemic and aims at supporting allergists and all physicians performing AIT in their current daily practice with clear recommendations on how to perform treatment during the pandemic and in SARS-CoV-2 infected patients.
dc.titleHandling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement
dc.title.alternativeALLERGY
dc.identifier.DOI-ID10.1111/all.14336
dc.identifier.volume75
dc.identifier.issue7
dc.identifier.startpage1546
dc.identifier.endpage1554
dc.identifier.issn/e-issn0105-4538
dc.identifier.issn/e-issn1398-9995


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record